The tight junction peptide designed to close the gaps celiac disease pries open—and why a promising Phase 2 became a cautionary Phase 3

Larazotide acetate is a synthetic octapeptide derived from a fragment of the Vibrio cholerae zonula occludens toxin—a bacterial protein that opens tight junctions in the intestinal lining. Discovered by Alessio Fasano's group at the University of Maryland, larazotide was engineered to do the opposite of its bacterial ancestor: instead of opening tight junctions, it closes them, blocking the pathological intestinal permeability that defines celiac disease at the tissue level.

The compound acts locally in the gut lumen. It is taken as an oral capsule and is designed to be minimally absorbed into the bloodstream—targeting the disease where it occurs, at the intestinal barrier. This local action gives larazotide an unusually clean safety profile for a peptide therapeutic: across Phase 1 through Phase 3 trials, its side effect profile was essentially indistinguishable from placebo.

But the Phase 3 primary endpoint failure is the defining fact in larazotide's story. In drug development, the Phase 3 primary endpoint is the regulatory gate. Larazotide demonstrated biological activity—it modulates tight junctions, it reduces permeability markers, it showed symptom improvement in Phase 2—but when the largest trial measured whether patients had fewer symptomatic days, the answer was not statistically significant. Whether this reflects a true lack of clinical benefit or the extraordinary difficulty of measuring celiac symptoms in patients already on a gluten-free diet is a question the data cannot fully answer.

Quick Facts: Larazotide Acetate at a Glance

What Is Larazotide?

Pronunciation: LAIR-uh-ZOH-tide

Your intestinal lining has a problem that most people never think about. The cells lining your gut are packed shoulder-to-shoulder, sealed together by protein complexes called tight junctions. These junctions are the gatekeepers—they decide what passes between cells and what stays out. In celiac disease, gluten triggers the release of zonulin, a protein that systematically disassembles those junctions, turning a sealed barrier into a leaky one. Gluten fragments slip through the gaps and into the immune system's territory, where they trigger the inflammatory cascade that damages the intestinal villi.

Larazotide acetate is a synthetic octapeptide designed to block that specific signal. It antagonizes the zonulin pathway—preventing ZO-1 phosphorylation and keeping tight junctions assembled even when gluten is present. The compound was derived, counterintuitively, from a fragment of a bacterial toxin (Vibrio cholerae's Zot protein) that normally opens tight junctions. Fasano's group at the University of Maryland recognized that a modified fragment of this toxin could be engineered to do the opposite—to close what celiac disease pries open.

The drug is taken as an oral capsule and acts locally in the gut lumen without significant systemic absorption. This means it targets the disease at the tissue level—the intestinal barrier—without exposing the rest of the body to the compound. It is not a replacement for a gluten-free diet. It is designed as an adjunct—a safety net for celiac patients who experience symptoms from the inadvertent gluten exposures that are nearly impossible to avoid completely, even with careful dietary adherence.

Origins and Discovery

The larazotide story begins with cholera. Vibrio cholerae—the bacterium that causes cholera—produces a toxin called Zot (zonula occludens toxin) that opens tight junctions in the intestinal epithelium, contributing to the massive fluid loss that defines the disease. In the 1990s, Alessio Fasano's laboratory at the University of Maryland was studying how Zot disrupts the intestinal barrier when they made a pivotal discovery: human intestinal cells produce their own tight junction–opening protein, which Fasano named zonulin.

Zonulin, it turned out, was pathologically elevated in celiac disease. The connection was immediate—gluten exposure in celiac patients triggers zonulin release, which opens tight junctions, which allows immunogenic gliadin peptides to cross the epithelial barrier, which triggers the T-cell–mediated inflammatory response that destroys intestinal villi. The tight junction was not just a bystander in celiac pathology; it was the gate through which the disease advanced.

Fasano's insight was that a fragment of the bacterial Zot protein could be modified to antagonize rather than activate the zonulin pathway. The resulting synthetic octapeptide—larazotide acetate (originally designated AT-1001)—was designed to compete with zonulin for the receptor that initiates tight junction disassembly, effectively locking the gate shut.

The compound was developed by Alba Therapeutics, later acquired by Innovate Biopharmaceuticals, which merged with 9 Meters Biopharma. The Phase 2 program generated encouraging data. The Phase 3 program did not meet its primary endpoint. As of 2026, the regulatory path forward remains uncertain.

Mechanism of Action

Tight Junction Biology

Intestinal tight junctions are multiprotein complexes that seal the paracellular space between adjacent epithelial cells. The key structural proteins—claudins, occludin, and zonula occludens proteins (ZO-1, ZO-2, ZO-3)—form a dynamic barrier that can open and close in response to physiological and pathological signals. In healthy gut function, tight junctions regulate paracellular permeability selectively—allowing water and small solutes through while blocking larger molecules and immune-reactive fragments.

The Zonulin Pathway

In celiac disease, gliadin (the immunogenic component of gluten) binds to the CXCR3 receptor on enterocytes, triggering the release of zonulin from the epithelial cells. Zonulin then acts in an autocrine/paracrine fashion, binding to PAR-2 (protease-activated receptor 2) and EGFR (epidermal growth factor receptor) on adjacent epithelial cells. This activates a signaling cascade—including protein kinase C and phosphorylation of ZO-1—that disassembles the tight junction complex, increasing paracellular permeability.

The increased permeability allows immunogenic gliadin peptides (33-mer and other fragments resistant to digestive enzymes) to cross the epithelial barrier and enter the lamina propria, where they are deamidated by tissue transglutaminase (tTG) and presented to HLA-DQ2/DQ8–restricted T cells. This triggers the adaptive immune response that damages intestinal villi—the hallmark of celiac disease.

How Larazotide Intervenes

Larazotide antagonizes the zonulin pathway at the receptor level. By competing with zonulin for PAR-2/EGFR binding, larazotide prevents the downstream phosphorylation cascade that disassembles ZO-1. The tight junction remains assembled. Paracellular permeability remains low. Gliadin fragment translocation is reduced.

Critically, larazotide acts in the gut lumen. It is designed to be minimally absorbed systemically—the target is the apical surface of enterocytes, where zonulin signaling occurs. This local mechanism of action limits systemic exposure and contributes to the placebo-like adverse event profile observed across clinical trials.

What Larazotide Does Not Do

Larazotide does not digest gluten. It does not prevent gluten from reaching the intestinal surface. It does not block the immune response once gliadin fragments have already crossed the barrier. It targets a single step in the celiac cascade—the opening of tight junctions—and leaves every other step untouched. This specificity is both its elegance and its limitation: if gliadin fragments reach the lamina propria through transcellular pathways (active transport through epithelial cells rather than between them), larazotide would not prevent the immune trigger.

Key Research Areas and Studies

Phase 2 Gluten Challenge Study (2012)

The proof-of-concept trial (PMID 28583154) enrolled 86 celiac patients on a gluten-free diet and challenged them with controlled gluten exposure while randomized to larazotide or placebo. Larazotide reduced intestinal permeability (measured by lactulose-mannitol ratio) and reduced gastrointestinal symptoms during gluten challenge compared to placebo.

This study established that larazotide's mechanism translated to measurable biological activity in humans—tight junction modulation was not just a laboratory finding but a clinical reality. The symptom improvement, while modest, provided rationale for the larger dose-finding trial.

Phase 2b Dose-Ranging Study (2015)

The larger Phase 2b trial (PMID 24662994) randomized 342 celiac patients on a gluten-free diet to larazotide 0.5 mg, 1 mg, 2 mg three times daily, or placebo. The 0.5 mg TID dose reduced CeD-GSRS (Celiac Disease Gastrointestinal Symptom Rating Scale) symptom scores compared to placebo. Notably, no dose-response relationship was observed—higher doses were not more effective than 0.5 mg, suggesting the therapeutic window may be narrow or that luminal concentration beyond a threshold does not provide additional benefit.

The 0.5 mg TID dose was selected for Phase 3 advancement based on this trial.

Phase 3 Trial (2022)

The Phase 3 trial enrolled approximately 600 celiac patients on a gluten-free diet and randomized them to larazotide 0.5 mg TID or placebo for 26 weeks. The primary endpoint was the change in number of symptomatic days per week (CeD-PRO abdominal domain).

The primary endpoint was not met. Larazotide did not demonstrate a statistically significant reduction in symptomatic days compared to placebo. Some secondary endpoints—including symptom severity scores and certain patient-reported outcomes—showed improvement, but the pre-specified primary endpoint failure is the defining regulatory result.

Why Phase 3 Failed—and What It Means

The Phase 3 failure does not necessarily mean larazotide does not work. Several factors complicate interpretation. Celiac patients on a gluten-free diet have highly variable baseline symptoms. The primary endpoint (number of symptomatic days) requires capturing inadvertent gluten exposures that are unpredictable and inconsistent. The placebo response rate in celiac symptom trials is historically high, which shrinks the detectable treatment effect. And the dose-response absence in Phase 2b may suggest the trial was not optimally designed to detect the compound's therapeutic signal.

None of these explanations change the regulatory fact: the Phase 3 primary endpoint was not met. In drug development, this is the gate, and larazotide did not clear it cleanly.

Claims vs. Evidence

The Human Evidence Landscape

Phase 1 Safety and Pharmacokinetics

Early Phase 1 studies established that larazotide acetate administered orally at doses up to 2 mg TID was well-tolerated with no significant systemic exposure. The compound's local gut action was confirmed—plasma concentrations were minimal, consistent with the design goal of luminal activity without systemic absorption.

Phase 2 Gluten Challenge (PMID 28583154)

Design: Randomized, double-blind, placebo-controlled. N=86 celiac patients on a gluten-free diet. Controlled gluten challenge (2.7 g gluten/day for 14 days) with concurrent larazotide or placebo.

Findings: Larazotide reduced intestinal permeability (lactulose-mannitol ratio) and gastrointestinal symptom scores during gluten challenge. The effect was most pronounced in the first week of gluten exposure.

Limitations: Small sample size. Controlled gluten challenge may not reflect real-world inadvertent exposure patterns. Short duration (14 days).

Phase 2b Dose-Ranging (PMID 24662994)

Design: Randomized, double-blind, placebo-controlled. N=342 celiac patients on a GFD. Four arms: larazotide 0.5 mg, 1 mg, 2 mg TID, or placebo. 12-week treatment period.

Findings: The 0.5 mg TID dose reduced CeD-GSRS symptom scores compared to placebo. No dose-response relationship—higher doses showed no additional benefit. CeD-GSRS composite score improvement was statistically significant for the 0.5 mg arm.

Limitations: Absence of dose-response is atypical and raises questions about the therapeutic mechanism at clinical doses. Symptom endpoints in celiac trials have high variability and high placebo response rates.

Phase 3 (2022)

Design: Randomized, double-blind, placebo-controlled. ~600 celiac patients on a GFD. Larazotide 0.5 mg TID vs. placebo. 26-week treatment.

Primary Endpoint: Change in number of symptomatic days per week (CeD-PRO abdominal domain). NOT MET.

Secondary Endpoints: Some symptom severity measures showed improvement. The magnitude of improvement on secondary endpoints was modest.

Limitations: High placebo response rate. Highly variable baseline symptom burden. The primary endpoint (symptom days) may not have been the optimal measure of larazotide's clinical effect—symptom severity may have been a more sensitive measure. The study was adequately powered for the pre-specified effect size, but the observed effect was smaller than anticipated.

Safety, Risks, and Limitations

Clinical Trial Safety Profile

Across all clinical trials (Phase 1 through Phase 3), larazotide's adverse event profile was remarkably similar to placebo. This is consistent with the compound's local gut action and minimal systemic absorption. The most commonly reported adverse events—nausea, abdominal pain, diarrhea, headache—occurred at similar rates in larazotide and placebo arms.

No serious adverse events attributable to larazotide were identified across the clinical program. No immunogenicity signals were detected. No drug interactions were identified.

Limitations

Not a standalone therapy. Larazotide was tested exclusively as an adjunct to a gluten-free diet. It does not replace dietary management. All trial participants maintained a gluten-free diet throughout.

Local action only. Larazotide targets paracellular permeability (the spaces between cells). It does not address transcellular transport of gliadin fragments, does not neutralize gliadin, and does not modulate the immune response. Its mechanism is narrowly targeted.

Investigational status. Larazotide is not commercially available. It cannot be purchased as a supplement, research chemical, or compounded pharmaceutical. Patients cannot access it outside of clinical trial or compassionate use contexts.

Phase 3 failure implications. The primary endpoint failure raises questions about whether tight junction modulation alone is sufficient to produce clinically meaningful symptom improvement in celiac patients already on a gluten-free diet. The residual symptom burden in well-managed celiac patients may involve mechanisms beyond paracellular permeability.

Safety Alert

Legal and Regulatory Status

FDA Status

Larazotide acetate is not FDA-approved for any indication. The Phase 3 clinical trial program for celiac disease was completed by 9 Meters Biopharma, but the primary endpoint was not met. As of 2026, the regulatory path forward is uncertain. 9 Meters Biopharma has explored additional data analyses and potential regulatory strategies, but no NDA filing has been announced.

International Status

Larazotide has not been approved by any regulatory authority worldwide. Development has been concentrated in the United States.

Intellectual Property

Larazotide patents are held by 9 Meters Biopharma (formerly Innovate Biopharmaceuticals, which acquired rights from Alba Therapeutics, Alessio Fasano's company). The compound is proprietary and not available for compounding or generic manufacture.

WADA Status

Larazotide is not on the WADA Prohibited List.

Research Protocols and Formulation Considerations

Formulation

Larazotide acetate is formulated as an oral capsule for enteric delivery. The capsule is designed to release the peptide in the small intestinal lumen, where tight junctions are the therapeutic target. The oral formulation is a significant advantage—most peptide therapeutics require injection. Larazotide's local gut action means it does not need to survive systemic circulation.

Storage

Clinical trial formulations were stored at 2–8°C (36–46°F). As an investigational drug, storage and handling information is limited to clinical trial protocols.

Reconstitution

Not applicable—larazotide is a finished oral capsule formulation. No reconstitution required.

Dosing in Published Research

The following table summarizes dosing protocols for Larazotide Acetate as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Published Research Dosing

The absence of a dose-response relationship is notable. In the Phase 2b trial, 0.5 mg, 1 mg, and 2 mg TID all showed similar effect magnitudes, with the 0.5 mg dose selected as the minimal effective dose. This flat dose-response curve may reflect the local mechanism—once sufficient drug is present in the gut lumen to block zonulin signaling, additional drug provides no incremental benefit.

Dosing in Self-Experimentation Communities

Larazotide is an investigational drug that is not available outside of clinical trials. There is no community use, no gray-market supply, and no self-experimentation data. The compound has never been available from research peptide vendors, compounding pharmacies, or supplement companies.

This section is intentionally sparse because there is nothing to report. Unlike most compounds on Peptidings, larazotide has no community use history—it exists only within the clinical development pipeline.

Combination Stacks

Research into Larazotide Acetate combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Larazotide Acetate with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Larazotide acetate represents one of the most scientifically elegant approaches to celiac disease management—a synthetic peptide that targets the specific molecular event (zonulin-mediated tight junction opening) that allows gluten to trigger the immune cascade. The compound acts locally in the gut, has an exceptional safety profile, and demonstrated biological activity in Phase 2 trials.

The Phase 3 primary endpoint failure is the defining fact. Despite reducing permeability markers and showing improvement on some symptom measures, larazotide did not demonstrate a statistically significant reduction in symptomatic days—the pre-specified regulatory endpoint. Whether this reflects genuine insufficiency of the therapeutic approach, suboptimal trial design for a notoriously difficult-to-measure condition, or both remains debated.

For celiac patients, larazotide represents a tantalizing near-miss: a drug with a clear mechanism, a clean safety record, and Phase 2 signals that did not translate cleanly to Phase 3 proof. The compound exists in the uncomfortable space between "biologically active" and "clinically proven."

Verdict Recapitulation

The biology is sound, the safety is clean, and the Phase 2 data showed measurable human activity. The Phase 3 primary endpoint failure prevents a "Strong Foundation" classification. But the combination of well-characterized mechanism, extensive clinical safety data, and demonstrated biological activity in humans justifies "Reasonable Bet"—there is enough evidence to take seriously, but not enough to call proven.

For readers considering Larazotide Acetate, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Larazotide Acetate

Further Reading and Resources

If you want to go deeper on Larazotide Acetate, the evidence landscape for gut health peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Gut Health Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Larazotide Acetate — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Leffler DA, Kelly CP, Green PHR, et al. (2015). "Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial." Gastroenterology, 148(7), 1311–1319.e6. PMID 24662994
2. Kelly CP, Green PHR, Murray JA, et al. (2013). "Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study." Alimentary Pharmacology & Therapeutics, 37(2), 252–262. PMID 28583154
3. Fasano A. (2000). "Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin." Annals of the New York Academy of Sciences, 915, 214–222. PMID 11193579
4. Fasano A. (2012). "Zonulin, regulation of tight junctions, and autoimmune diseases." Annals of the New York Academy of Sciences, 1258(1), 25–33. PMID 22731712
5. Leffler DA, Kelly CP, Abdallah HZ, et al. (2012). "A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge." American Journal of Gastroenterology, 107(10), 1554–1562. PMID 22825364
6. Fasano A, Not T, Wang W, et al. (2000). "Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease." Lancet, 355(9214), 1518–1519. PMID 10801176
7. Paterson BM, Lammers KM, Arrieta MC, et al. (2007). "The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects." Alimentary Pharmacology & Therapeutics, 26(5), 757–766. PMID 17697209
8. Sturgeon C, Fasano A. (2016). "Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases." Tissue Barriers, 4(4), e1251384. PMID 28123927
9. 9 Meters Biopharma. (2022). "Phase 3 top-line results for larazotide acetate in celiac disease." Press release
10. Celiac Disease Foundation. (2025). "Larazotide acetate pipeline status." Clinical trials tracker

---